| Revenue growth | FY26 revenue up 6.4% YoY; Q4FY26 revenue up 11.2% YoY. |
|---|---|
| Margins | FY26 Gross Margin expanded 310bps to 59.7%; EBITDA margin up 140bps to 19%. |
| Demand visibility | Growth led by Ex-US markets; US stable but seasonally impacted. |
| Management confidence | Confident in long-term sustainable growth despite external headwinds. |
Growth
FY26 EBITDA grew 15.3% to ₹9,253m; Operational EPS rose 50% to ₹56.2. Ex-US markets grew 21% YoY.
Outlook
Aims for ~$400m North America revenue by FY28; growth recovery expected in H2FY27 with new launches.
Risks
US business impacted by weak flu season and slower-than-expected quota allocation for controlled substances.
Earnings Call filed with BSE, NSE: STAR. Summary written with AI assistance from the document.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,184.90
- Market cap
- ₹10,922 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 17.8×Sector 50.4×
- Promoter holding
- 27.91%+0.00% QoQ
- FII holding
- 28.40%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Business Update
Strides Pharma Science received a Form 483 with three observations following a routine USFDA inspection at its Alathur formulations facility. The company will respond within stipulated timelines.
Strides Pharma Science Earnings Call Transcript: Key Takeaways
Strides Pharma Science reported Q1 FY27 results with 13% YoY revenue growth and EBITDA margins maintained at 18.2%. Strategy focuses on Ex-US growth and US portfolio diversification.
- Call
- Guides 32% growth
Strides Pharma Science Investor Presentation: Key Takeaways
Strides Q1FY27 revenue grew 13% YoY to ₹12,654m, led by a 17% surge in Ex-US markets. Operational PAT stood at ₹1,231m.
Strides Pharma Science Q1 FY27 Results: Net Profit ₹165.5 Cr, Up 56.7% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,265 Cr (+13.0% YoY) and net profit of ₹165.5 Cr (+56.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹165.5 Cr · +56.7% YoY
Strides Pharma Science Earnings Call: Key Takeaways
Strides Pharma reported its highest ever EBITDA and operational PAT for FY26, driven by significant geographical diversification and a structural shift toward non-U.S. markets.
Strides Pharma Science Q4 FY26 Results: Net Profit ₹129.3 Cr, Up 51.1% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,324 Cr (+11.2% YoY) and net profit of ₹129.3 Cr (+51.1% YoY) for Q4 FY26.
- Key figure
- Net profit ₹129.3 Cr · +51.1% YoY